Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
No one on the platform currently holds LUMO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 213,814 | $827.5K |
No one on the platform has traded LUMO yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1M | -26.7% | $-1.58 | $-2.14–$-1.28 | — | 3 |
| 2027 | $100M | +9679.8% | $-0.82 | $-0.82–$-0.82 | — | 1 |
| 2028 | $5M | -95.1% | $-0.70 | $-0.70–$-0.70 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2024-11-07 | $-0.56 | $-0.90 | -60.7% |
| 2024-08-01 | $-1.26 | $-0.93 | +26.2% |
| 2024-05-14 | $-1.21 | $-1.29 | -6.6% |
| 2024-03-07 | $-1.18 | $-1.17 | +0.8% |
| 2023-11-07 | $-1.10 | $-1.04 | +5.5% |
| 2023-08-09 | $-1.06 | $-1.09 | -2.8% |
| 2023-05-03 | $-1.12 | $-0.89 | +20.5% |
| 2023-03-01 | $-0.95 | $-0.98 | -3.2% |
| $298M |
| — |
| LIANYLianBio | $0.02 | -40.26% | $3M | — |
| MGTAMagenta Therapeutics, Inc. | $0.70 | -7.74% | $42M | — |
Source: Financial Modeling Prep · peers by sector/industry
$LUMO Looks like they have finally started enrolling in the phase III “The actual date on which the first participant was enrolled in a clinical study.” Actual start date says 5/20/26! First patient has been enrolled!! https://clinicaltrials.gov/study/NCT06948214
View on StockTwits ↗
$LUMO Lumos Pharma Reports Promising Second Quarter 2024 Results and Provides Update on Planned Phase 3 Trial for LUM-201 https://beyondspx.com/article/lumos-pharma-lumo-navigating-the-rare-disease-landscape-with-promising-oral-therapeutics
View on StockTwits ↗
$LUMO Lumo and their pointless drug was just another example of private money from early lumo investers needing a vehicle to escape when they grabbed newlink genetics and their $115 million cash pile. 6 bagger off the bottom and left for trash sweepers.
View on StockTwits ↗
Two acquisitions closing, to be delisted tonight after the close of extended hours trading - $AY to be acquired by Energy Capital Partners, $22.00 cash - $LUMO to be acquired by Double Point Ventures, $4.25 cash + 1 CVR More Info : https://www.sec.gov/Archives/edgar/data/1601072/000114036124045048/ef20038091_ex99-1.htm https://www.sec.gov/Archives/edgar/data/1126234/000119312524268141/d880311dsc14d9a.htm
View on StockTwits ↗
$LUMO Closed my position for a loss. Not happy about it. I do hate this company now.
View on StockTwits ↗
$LUMO Anyone have a feel for the trading behavior on this? Seems to be a huge amount of selling built up around $4.32. is it large positions selling out rather than tendering, or is it something more nefarious?
View on StockTwits ↗$LUMO Lumos Pharma (LUMO): Navigating the Rare Disease Landscape with Promising Oral Therapeutics https://beyondspx.com/article/lumos-pharma-lumo-navigating-the-rare-disease-landscape-with-promising-oral-therapeutics
View on StockTwits ↗
$TSLA holding till $350. $VSTM and $LUMO next on my list.
View on StockTwits ↗$EBS $CHRS $GRI $LUMO to watch for next 2-3 weeks.
View on StockTwits ↗$EBS $LUMO is free money with $4.25 BO offer and 3 years potential premium on the milestones upto $7.
View on StockTwits ↗$ARDX $LUMO might get counter offer for BO. Keep and eye
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.